TBPH
Theravance BiopharmaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
TBPH vs peer average
39/100
TBPH vs. peer average (D vs. C)
Grade spread
B 2 · C 4 · D 3 · F 1
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
ABUS is the first available peer comparator.
Arbutus is a similar-cap biopharma name, but it is more pipeline-led than TBPH; the comparison mostly highlights that TBPH is now being valued more on cash balance, commercial royalty streams, and strategic optionality than on a near-term clinical rerating.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
TBPH
Theravance Biopharma
ABUS
Arbutus Biopharma
Grade
D
C
Momentum
30
46
Value
57
41
Sentiment
46
67
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Mixed
Grade position vs ABUS
TBPH / ABUS
Grade Position
Below peers
TBPH vs. peer average (D vs. C)
39/100
Momentum
30
ABUSValue
57
TBPHSentiment
46
ABUSRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs TBPH
ABUS is the first peer returned for this comparison set.